RETRACTED: Relationship Between Aldosterone Synthase CYP1A1 MspI Gene                     Polymorphism and Prostate Cancer Risk

Ou, Chao; Zhao, Yan; Liu, Jianghua; Zhu, Bin; Li, Peizhang; Zhao, Hongda

doi:10.1177/1533034615625519

Cited by 4 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In liver cancer cells, over-expression of CYP1A1 induced by plant natural products has been associated with Aryl-hydrocarbon Receptor transformation [36,37]. Furthermore, as a steroid-metabolizing enzyme, CYP1A1 is part of cancer metabolic processes relevant to steroid hormone responsive tumors, such as breast cancer, ovarian cancer, and prostate cancer [38][39][40][41]. Therefore, CYP1A1 may be of particular interest in understanding the mechanism of action of CKI on cancer cells.…”

Section: Discussionmentioning

confidence: 99%

The effect of compound kushen injection on cancer cells: Integrated identification of candidate molecular mechanisms

Cui¹,

Qu²,

Harata-Lee³

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Traditional Chinese Medicine (TCM) preparations are often extracts of single or multiple herbs containing hundreds of compounds, and hence it has been difficult to study their mechanisms of action. Compound Kushen Injection (CKI) is a complex mixture of compounds extracted from two medicinal plants and has been used in Chinese hospitals to treat cancer for over twenty years. To demonstrate that a systematic analysis of molecular changes resulting from complex mixtures of bioactives from TCM can identify a core set of differentially expressed (DE) genes and a reproducible set of candidate pathways. We used in vitro cancer models to measure the effect of CKI on cell cycle phases and apoptosis, and correlated those phenotypes with CKI induced changes in gene expression. We treated two cancer cell lines with or without CKI and assessed the resulting phenotypes by employing cell viability and proliferation assays. Based on these results, we carried out high-throughput transcriptome data analysis to identify genes and candidate pathways perturbed by CKI. We integrated these differential gene expression results with previously reported results and carried out validation of selected differentially expressed genes. CKI induced cell-cycle arrest and apoptosis in the cancer cell lines tested. In these cells CKI also altered the expression of 363 core candidate genes associated with cell cycle, apoptosis, DNA replication/repair, and various cancer pathways. Of these, 7 are clinically relevant to cancer diagnosis or therapy, 14 are cell cycle regulators, and most of these 21 candidates are downregulated by CKI. Comparison of our core candidate genes to a database of plant medicinal compounds and their effects on gene expression identified one-to-one, one-tomany and many-to-many regulatory relationships between compounds in CKI and DE genes. By identifying genes and promising candidate pathways associated with CKI treatment based on our transcriptome-based analysis, we have shown that this approach is useful for the systematic analysis of molecular changes resulting from complex mixtures of bioactives.

show abstract

Section: Discussionmentioning

confidence: 99%

The effect of compound kushen injection on cancer cells: Integrated identification of candidate molecular mechanisms

Cui¹,

Qu²,

Harata-Lee³

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Numerous studies and also the recent meta-analyses showed the association between these SNVs and PCa risk [84][85][86].…”

Section: Carcinogen Metabolismmentioning

confidence: 96%

Genetic Association Studies on Prostate Cancer

Nikolic¹,

Savić‐Pavićević²,

Brajušković³

2016

Prostate Cancer - Leading-Edge Diagnostic Procedures and Treatments

View full text Add to dashboard Cite

The modern research on molecular basis of prostate cancer (PCa) development includes studies aiming to identify potential genetic markers which could be used in diagnostics and/or monitoring of PCa. Genome-wide association studies (GWASs) have identified over 75 variants associated with PCa risk. One of the major PCarelated regions identified through GWASs is found to be a segment of 8q24. Other important PCa-susceptibility regions are 17q12, 17q24, 10q11, and 19q13. Candidategene based approach has also provided evidence of association between PCa risk and genetic variants located in functionally significant genes (both protein-coding and noncoding RNA genes) involved in normal prostatic cell growth, malignant transformation, or in the development of metastases. Nevertheless, the success of these studies is questionable, since numerous candidates for PCa-susceptibility variants were identified, but these results failed to replicate. The main aim of both types of genetic association studies on PCa is the identification of potential PCa genetic markers which could be used for constructing reliable algorithms for evaluating the risk for PCa development and/or PCa progression.

show abstract

The Effect of Compound Kushen Injection on Cancer Cells: Integrated Identification of Candidate Molecular Mechanisms

Cui

Harata-Lee

et al. 2018

Preprint

View full text Add to dashboard Cite

Background: Because Traditional Chinese Medicine (TCM) preparations are often combinations of multiple herbs containing hundreds of compounds, they have been di cult to study. Compound Kushen Injection (CKI) is a complex mixture cancer treatment used in Chinese hospitals for over twenty years.Purpose: To demonstrate that a systematic analysis of molecular changes resulting from complex mixtures of bioactives from TCM can identify a core set of di↵erentially expressed (DE) genes and a reproducible set of candidate pathways. Study Design:We used a cancer cell culture model to measure the e↵ect of CKI on cell cycle phases, apoptosis and correlate those phenotypes with CKI induced changes in gene expression. Methods:We treated cancer cells with CKI in order to generate and analyse high-throughput transcriptome data from two cancer cell lines. We integrated these di↵erential gene expression results with previously reported results.Results: CKI induced cell-cycle arrest and apoptosis and altered the expression of 363 core candidate genes associated with cell cycle, apoptosis, DNA replication/repair and various cancer pathways. Of these, 7 are clinically relevant to cancer diagnosis or therapy and 14 are cell cycle regulators, and most of these 21 candidates are downregulated by CKI. Comparison of our core candidate genes to a database of plant medicinal compounds and their e↵ects on gene expression identified one-to-one, one-to-many and many-to-many regulatory relationships between compounds in CKI and DE genes.Conclusions: By identifying promising candidate pathways and genes associated with CKI based on our transcriptome-based analysis, we have shown this approach is useful for the systematic analysis of molecular changes resulting from complex mixtures of bioactives.The treatments of choice for cancer are often radiotherapy and/or chemotherapy, and while 2 these can be e↵ective, they can cause quite serious side-e↵ects, including death. These side-e↵ects 3 have driven the search for adjuvant therapies to both mitigate side-e↵ects and/or potentiate the 4 e↵ectiveness of existing therapies. Traditional Chinese Medicine (TCM) is one of the options for 5 adjuvant therapies, particularly in China, but increasingly so in the West. While clinical trial data 6 on the e↵ectiveness of TCM is currently limited, it remains an attractive option because of its long 7 history and because its potential e↵ectiveness is believed to result from the cumulative e↵ects of 8 multiple compounds on multiple targets [13]. Because TCM often has not been subjected to 9 rigorous evidence-based assessment and because it is based on an alternative theoretical system 10 compared to Western medicine, adoption of its plant derived therapeutics has been slow. 11In this report, we continue to characterize the molecular e↵ects of Compound Kushen Injection 12 3 (CKI) on cancer cells. CKI has been approved by the State Food and Drug Administration 13 (SFDA) of China for clinical use since 1995 [31] (State medical license no. Z14021231). CKI is an 14 herb...

show abstract

RETRACTED: Relationship Between Aldosterone Synthase CYP1A1 MspI Gene Polymorphism and Prostate Cancer Risk

Cited by 4 publications

References 14 publications

The effect of compound kushen injection on cancer cells: Integrated identification of candidate molecular mechanisms

The effect of compound kushen injection on cancer cells: Integrated identification of candidate molecular mechanisms

Genetic Association Studies on Prostate Cancer

The Effect of Compound Kushen Injection on Cancer Cells: Integrated Identification of Candidate Molecular Mechanisms

Contact Info

Product

Resources

About